Skip to main content
Erschienen in: International Archives of Occupational and Environmental Health 2/2014

01.02.2014 | Original Article

Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers

verfasst von: Michael K. Felten, Khaled Khatab, Lars Knoll, Thomas Schettgen, Hendrik Müller-Berndorff, Thomas Kraus

Erschienen in: International Archives of Occupational and Environmental Health | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In patients developing malignant pleural mesothelioma (MPM) or lung cancer, using effective tumour markers is the quickest way to ensure early diagnosis and improve survival time. The aim of our study was to assess the influence of age and asbestos exposure on the blood levels of the proposed tumour markers, mesothelin and osteopontin, and to determine the change of these markers over time.

Methods

We analysed 3,329 blood samples of 2,262 participants including 1,894 formerly asbestos-exposed power industry workers, a mixed group of 266 participants with an unknown history of asbestos exposure and a group of 102 non-asbestos-exposed controls. Marker concentrations were determined using commercial ELISA kits.

Results

While age had a strong influence on marker levels, there was no association between exposure duration or benign asbestos-related disease and marker levels. In order to assess the maximum increase that can be expected to occur in asbestos-exposed workers those with an at least 10 % increase were selected (n = 290 for mesothelin and n = 81 for osteopontin). The 95th percentile of the annual change was 0.402 nmol/l for mesothelin and 334 ng/ml for osteopontin. In two patients with MPM and five with lung cancer, we could obtain more than one marker result before the diagnosis was made. Both MPM patients showed a steep increase of mesothelin levels.

Conclusions

Fixed cut-off values for deciding between intensive clinical work-up and continued surveillance appeared inadequate for the evaluated markers. While general conclusions cannot be drawn, we can say that the results of the two patients would be consistent with a mesothelin increase between 6 and 18 months before clinical symptoms developed.
Literatur
Zurück zum Zitat Creaney J, Robinson BW (2009) Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 15:366–370CrossRef Creaney J, Robinson BW (2009) Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 15:366–370CrossRef
Zurück zum Zitat Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW (2010) Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 19:2238–2246CrossRef Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW (2010) Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 19:2238–2246CrossRef
Zurück zum Zitat Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R (2007) Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 13:5076–5081CrossRef Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R (2007) Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 13:5076–5081CrossRef
Zurück zum Zitat Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R (2011) Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 6:1587–1593CrossRef Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R (2011) Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 6:1587–1593CrossRef
Zurück zum Zitat Felten MK, Knoll L, Eisenhawer C, Ackermann D, Khatab K, Hudepohl J, Zschiesche W, Kraus T (2010) Retrospective exposure assessment to airborne asbestos among power industry workers. J Occup Med Toxicol 5:15CrossRef Felten MK, Knoll L, Eisenhawer C, Ackermann D, Khatab K, Hudepohl J, Zschiesche W, Kraus T (2010) Retrospective exposure assessment to airborne asbestos among power industry workers. J Occup Med Toxicol 5:15CrossRef
Zurück zum Zitat Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P (2007) Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13:2928–2935CrossRef Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P (2007) Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13:2928–2935CrossRef
Zurück zum Zitat Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A (2009) Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis 71:31–38 Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A (2009) Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis 71:31–38
Zurück zum Zitat Henderson DW, Rodelsperger K, Woitowitz HJ, Leigh J (2004) After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997–2004. Pathology 36:517–550CrossRef Henderson DW, Rodelsperger K, Woitowitz HJ, Leigh J (2004) After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997–2004. Pathology 36:517–550CrossRef
Zurück zum Zitat Ho M, Bera TK, Willingham MC, Onda M, Hassan R, Fitzgerald D, Pastan I (2007) Mesothelin expression in human lung cancer. Clin Cancer Res 13:1571–1575CrossRef Ho M, Bera TK, Willingham MC, Onda M, Hassan R, Fitzgerald D, Pastan I (2007) Mesothelin expression in human lung cancer. Clin Cancer Res 13:1571–1575CrossRef
Zurück zum Zitat Hollevoet K, van Cleemput J, Thimpont J, de Vuyst P, Bosquee L, Nackaerts K, Germonpre P, Vansteelandt S, Kishi Y, Delanghe JR, van Meerbeeck JP (2011) Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. J Thorac Oncol 6:889–895CrossRef Hollevoet K, van Cleemput J, Thimpont J, de Vuyst P, Bosquee L, Nackaerts K, Germonpre P, Vansteelandt S, Kishi Y, Delanghe JR, van Meerbeeck JP (2011) Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. J Thorac Oncol 6:889–895CrossRef
Zurück zum Zitat Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, Urban N, Drescher CW (2008) Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 17:2480–2487CrossRef Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, Urban N, Drescher CW (2008) Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 17:2480–2487CrossRef
Zurück zum Zitat McIntosh MW, Urban N, Karlan B (2002) Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev 11:159–166 McIntosh MW, Urban N, Karlan B (2002) Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev 11:159–166
Zurück zum Zitat Neragi-Miandoab S (2006) Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 29:14–19CrossRef Neragi-Miandoab S (2006) Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 29:14–19CrossRef
Zurück zum Zitat Park EK, Thomas PS, Johnson AR, Yates DH (2009) Osteopontin levels in an asbestos-exposed population. Clin Cancer Res 15:1362–1366CrossRef Park EK, Thomas PS, Johnson AR, Yates DH (2009) Osteopontin levels in an asbestos-exposed population. Clin Cancer Res 15:1362–1366CrossRef
Zurück zum Zitat Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH (2010) Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 48:869–874 Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH (2010) Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 48:869–874
Zurück zum Zitat Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564–1573CrossRef Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564–1573CrossRef
Zurück zum Zitat Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J (2008) Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85:265–272 (discussion 272)CrossRef Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J (2008) Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85:265–272 (discussion 272)CrossRef
Zurück zum Zitat Roberts HC, Patsios DA, Paul NS, Deperrot M, Teel W, Bayanati H, Shepherd F, Johnston MR (2009) Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol 4:620–628CrossRef Roberts HC, Patsios DA, Paul NS, Deperrot M, Teel W, Bayanati H, Shepherd F, Johnston MR (2009) Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol 4:620–628CrossRef
Zurück zum Zitat Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612–1616CrossRef Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612–1616CrossRef
Zurück zum Zitat Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366:397–408CrossRef Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366:397–408CrossRef
Zurück zum Zitat Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, Alfageme Michavila I, Quero Martinez A, Diego Roza C, Leon Jimenez A, Isidro Montes I, Cebollero Rivas P (2009) Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 18:646–650CrossRef Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, Alfageme Michavila I, Quero Martinez A, Diego Roza C, Leon Jimenez A, Isidro Montes I, Cebollero Rivas P (2009) Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 18:646–650CrossRef
Zurück zum Zitat Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K (2008) Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 61:235–243CrossRef Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K (2008) Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 61:235–243CrossRef
Zurück zum Zitat Scherpereel A, Lee YC (2007) Biomarkers for mesothelioma. Curr Opin Pulm Med 13:339–443CrossRef Scherpereel A, Lee YC (2007) Biomarkers for mesothelioma. Curr Opin Pulm Med 13:339–443CrossRef
Zurück zum Zitat Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P (2006) Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173:1155–1160CrossRef Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P (2006) Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173:1155–1160CrossRef
Zurück zum Zitat Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T (2008) Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 3:1317–1324CrossRef Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T (2008) Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 3:1317–1324CrossRef
Zurück zum Zitat Stewart DJ, Edwards JG, Smythe WR, Waller DA, O’Byrne KJ (2004) Malignant pleural mesothelioma—an update. Int J Occup Environ Health 10:26–39CrossRef Stewart DJ, Edwards JG, Smythe WR, Waller DA, O’Byrne KJ (2004) Malignant pleural mesothelioma—an update. Int J Occup Environ Health 10:26–39CrossRef
Zurück zum Zitat Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, Decamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–63 (discussion 63–65)CrossRef Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, Decamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–63 (discussion 63–65)CrossRef
Zurück zum Zitat Teschke K, Olshan AF, Daniels JL, de Roos AJ, Parks CG, Schulz M, Vaughan TL (2002) Occupational exposure assessment in case-control studies: opportunities for improvement. Occup Environ Med 59:575–593 (discussion 594)CrossRef Teschke K, Olshan AF, Daniels JL, de Roos AJ, Parks CG, Schulz M, Vaughan TL (2002) Occupational exposure assessment in case-control studies: opportunities for improvement. Occup Environ Med 59:575–593 (discussion 594)CrossRef
Zurück zum Zitat Vickers AJ, Savage C, O’Brien MF, Lilja H (2009) Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27:398–403CrossRef Vickers AJ, Savage C, O’Brien MF, Lilja H (2009) Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27:398–403CrossRef
Zurück zum Zitat Weber DG, Johnen G, Taeger D, Weber A, Gross IM, Pesch B, Kraus T, Bruning T, Gube M (2010) Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum. Biomark Insights 5:1–8CrossRef Weber DG, Johnen G, Taeger D, Weber A, Gross IM, Pesch B, Kraus T, Bruning T, Gube M (2010) Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum. Biomark Insights 5:1–8CrossRef
Zurück zum Zitat Weill H, Hughes JM, Churg AM (2004) Changing trends in US mesothelioma incidence. Occup Environ Med 61:438–441CrossRef Weill H, Hughes JM, Churg AM (2004) Changing trends in US mesothelioma incidence. Occup Environ Med 61:438–441CrossRef
Zurück zum Zitat Zervos MD, Bizekis C, Pass HI (2008) Malignant mesothelioma 2008. Curr Opin Pulm Med 14:303–309CrossRef Zervos MD, Bizekis C, Pass HI (2008) Malignant mesothelioma 2008. Curr Opin Pulm Med 14:303–309CrossRef
Metadaten
Titel
Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers
verfasst von
Michael K. Felten
Khaled Khatab
Lars Knoll
Thomas Schettgen
Hendrik Müller-Berndorff
Thomas Kraus
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
International Archives of Occupational and Environmental Health / Ausgabe 2/2014
Print ISSN: 0340-0131
Elektronische ISSN: 1432-1246
DOI
https://doi.org/10.1007/s00420-013-0853-1

Weitere Artikel der Ausgabe 2/2014

International Archives of Occupational and Environmental Health 2/2014 Zur Ausgabe